Skip to main content

TOP - August 2018, Vol 11, No 2

Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
By Phoebe Starr
Breast Cancer
TOP - August 2018, Vol 11, No 2
A new study presented at the 2018 American Association for Cancer Research meeting suggests that HER2 mutations can be acquired during metastatic cancer and their development represents a previously unreported mechanism of resistance to treatment. Read More ›
Using Cancer Drugs Wisely to Control Costs: Targeted Therapies May Hold the Key
Using Cancer Drugs Wisely to Control Costs: Targeted Therapies May Hold the Key
By Gail Thompson
Best Practices
TOP - August 2018, Vol 11, No 2

“It is time for us to bury the concept of maximum-tolerated dose in the world of targeted therapy,” according to Allen S. Lichter, MD, FASCO.

Read More ›
FDA Taking Steps to Promote Generic Drug Competition and Improve Patient Access to Therapies
FDA Taking Steps to Promote Generic Drug Competition and Improve Patient Access to Therapies
By Eileen Koutnik-Fotopoulos
Healthcare Policy
TOP - August 2018, Vol 11, No 2

While the industry does its part to improve the quality and completeness of applications, the FDA is taking action to enhance the efficiency of its review process.

Read More ›
Noteworthy Numbers: Non-Hodgkin Lymphoma
Noteworthy Numbers
TOP - August 2018, Vol 11, No 2

Patients with indolent subtypes of NHL have a relatively good prognosis with a median survival as long as 20 years, although these subtypes of the disease are typically not curable in advanced stages.

Read More ›

Page 2 of 2